[{"address1": "825 Industrial Road", "address2": "Suite 500", "city": "San Carlos", "state": "CA", "zip": "94070", "country": "United States", "phone": "650 597 5002", "website": "https://www.allakos.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.", "fullTimeEmployees": 131, "companyOfficers": [{"maxAge": 1, "name": "Dr. Robert  Alexander Ph.D.", "age": 54, "title": "CEO & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 1504567, "exercisedValue": 0, "unexercisedValue": 1861500}, {"maxAge": 1, "name": "Dr. Adam L. Tomasi Ph.D.", "age": 54, "title": "President", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 1149938, "exercisedValue": 0, "unexercisedValue": 992256}, {"maxAge": 1, "name": "Mr. Baird  Radford III", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 731346, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 10, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.2976, "open": 0.2869, "dayLow": 0.2775, "dayHigh": 0.3194, "regularMarketPreviousClose": 0.2976, "regularMarketOpen": 0.2869, "regularMarketDayLow": 0.2775, "regularMarketDayHigh": 0.3194, "beta": 0.771, "forwardPE": -0.5147325, "volume": 3536318, "regularMarketVolume": 3536318, "averageVolume": 2235628, "averageVolume10days": 3082180, "averageDailyVolume10Day": 3082180, "bid": 0.3114, "ask": 0.3188, "bidSize": 400, "askSize": 400, "marketCap": 27937744, "fiftyTwoWeekLow": 0.23, "fiftyTwoWeekHigh": 1.69, "fiftyDayAverage": 0.8618, "twoHundredDayAverage": 0.9244, "currency": "USD", "enterpriseValue": -25775246, "floatShares": 59659212, "sharesOutstanding": 89343600, "sharesShort": 2438587, "sharesShortPriorMonth": 801350, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0273, "heldPercentInsiders": 0.021259999, "heldPercentInstitutions": 0.95416, "shortRatio": 0.54, "shortPercentOfFloat": 0.0387, "impliedSharesOutstanding": 91606800, "bookValue": 0.814, "priceToBook": 0.38415232, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -178744992, "trailingEps": -2.03, "forwardEps": -0.63, "enterpriseToEbitda": 0.167, "52WeekChange": -0.75409836, "SandP52WeekChange": 0.22903383, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ALLK", "underlyingSymbol": "ALLK", "shortName": "Allakos Inc.", "longName": "Allakos Inc.", "firstTradeDateEpochUtc": 1532007000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "42c6c158-c38d-3e00-b41e-7332226eb737", "messageBoardId": "finmb_225312313", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.3127, "targetHighPrice": 0.4, "targetLowPrice": 0.3, "targetMeanPrice": 0.35, "targetMedianPrice": 0.35, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 4, "totalCash": 92715000, "totalCashPerShare": 1.038, "ebitda": -154723008, "totalDebt": 39002000, "quickRatio": 5.802, "currentRatio": 6.079, "debtToEquity": 53.616, "returnOnAssets": -0.48749, "returnOnEquity": -1.21684, "freeCashflow": -53340000, "operatingCashflow": -105398000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]